638 results on '"Khoury, Thaer"'
Search Results
202. Delay to formalin fixation effect on breast biomarkers
- Author
-
Khoury, Thaer, primary, Sait, Sheila, additional, Hwang, Helena, additional, Chandrasekhar, Rameela, additional, Wilding, Gregory, additional, Tan, Dongfeng, additional, and Kulkarni, Swati, additional
- Published
- 2009
- Full Text
- View/download PDF
203. Mammary Paget's disease and extra‐mammary Paget's disease: two morphologically similar but biologically different diseases
- Author
-
Liu, Weiguo, primary, Iqbal, Jabad, additional, and Khoury, Thaer, additional
- Published
- 2009
- Full Text
- View/download PDF
204. Apoptosis-Related (Survivin, Bcl-2), Tumor Suppressor Gene (p53), Proliferation (Ki-67), and Non-Receptor Tyrosine Kinase (Src) Markers Expression and Correlation With Clinicopathologic Variables in 60 Thymic Neoplasms
- Author
-
Khoury, Thaer, primary, Arshad, Ayesha, additional, Bogner, Paul, additional, Ramnath, Nithya, additional, Zhang, Shaozeng, additional, Chandrasekhar, Rameela, additional, Wilding, Gregory, additional, Alrawi, Sadir, additional, and Tan, Dongfeng, additional
- Published
- 2009
- Full Text
- View/download PDF
205. Genetic and Molecular Abnormalities in Cholangiocarcinogenesis
- Author
-
HASSID, VICTOR J., primary, ORLANDO, FRANK A., additional, AWAD, ZIAD T., additional, TAN, DONGFENG, additional, KHOURY, THAER, additional, AHMED, BESTOUN H., additional, and ALRAWI, SADIR J., additional
- Published
- 2009
- Full Text
- View/download PDF
206. TLE3 as a candidate biomarker of response to taxane therapy
- Author
-
Kulkarni, Swati A, primary, Hicks, David G, additional, Watroba, Nancy L, additional, Murekeyisoni, Christine, additional, Hwang, Helena, additional, Khoury, Thaer, additional, Beck, Rodney A, additional, Ring, Brian Z, additional, Estopinal, Noel C, additional, Schreeder, Marshall T, additional, Seitz, Robert S, additional, and Ross, Douglas T, additional
- Published
- 2009
- Full Text
- View/download PDF
207. Eukaryotic Initiation Factor-4E and Cyclin D1 Expression Associated with Patient Survival in Lung Cancer
- Author
-
Khoury, Thaer, primary, Alrawi, Sadir, additional, Ramnath, Nithva, additional, Li, Qiang, additional, Grimm, Melissa, additional, Black, Jennifer, additional, and Tan, Dongfeng, additional
- Published
- 2009
- Full Text
- View/download PDF
208. In Vivo Translational Drug Development Model in Pancreatic Cancer
- Author
-
Vinjamaram, Sanjay, primary, Gibbs, John, additional, Khoury, Thaer, additional, Repasky, Elizabeth, additional, Hylander, Bonnie, additional, and Iyer, Renuka, additional
- Published
- 2008
- Full Text
- View/download PDF
209. Genetic variants in one-carbon metabolism genes and breast cancer risk in European American and African American women.
- Author
-
Gong, Zhihong, Yao, Song, Zirpoli, Gary, David Cheng, Ting‐Yuan, Roberts, Michelle, Khoury, Thaer, Ciupak, Gregory, Davis, Warren, Pawlish, Karen, Jandorf, Lina, Bovbjerg, Dana H., Bandera, Elisa V., and Ambrosone, Christine B.
- Abstract
Folate-mediated one-carbon metabolism plays critical roles in DNA synthesis, repair and DNA methylation. The impact of single nucleotide polymorphisms (SNPs) in folate-metabolizing enzymes has been investigated in risk of breast cancer among European or Asian populations, but not among women of African ancestry. We conducted a comprehensive analysis of SNPs in eleven genes involved in one-carbon metabolism and risk of breast cancer in 1,275 European-American (EA) and 1,299 African-American (AA) women who participated in the Women's Circle of Health Study. Allele frequencies varied significantly between EA and AA populations. A number of these SNPs, specifically in genes including MTR, MTRR, SHMT1, TYMS and SLC19A1, were associated with overall breast cancer risk, as well as risk by estrogen receptor (ER) status, in either EA or AA women. Associations appeared to be modified by dietary folate intake. Although single-SNP associations were not statistically significant after correcting for multiple comparisons, polygenetic score analyses revealed significant associations with breast cancer risk. Per unit increase of the risk score was associated with a modest 19 to 50% increase in risk of breast cancer overall, ER positive or ER negative cancer (all p < 0.0005) in EAs or AAs. In summary, our data suggest that one-carbon metabolizing gene polymorphisms could play a role in breast cancer and that may differ between EA and AA women. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
210. Nomogram to predict the likelihood of upgrade of atypical ductal hyperplasia diagnosed on a core needle biopsy in mammographically detected lesions.
- Author
-
Khoury, Thaer, Chen, Xiwei, Wang, Dan, Kumar, Prasanna, Qin, Maochun, Liu, Song, and Turner, Bradley
- Subjects
- *
HYPERPLASIA , *CORE needle biopsy , *SURGICAL excision , *HORMONE therapy , *NOMOGRAPHY (Mathematics) , *LOGISTIC regression analysis - Abstract
Aims To estimate the likelihood of the upgrade for atypical ductal hyperplasia ( ADH) diagnosed on a core needle biopsy of a mammographically detected lesion. Methods and results A total of 203 consecutive ADH cases diagnosed on core biopsy in mammographically detected lesions and having subsequent surgical excision were reviewed. The pathological features of ADH were assessed with multivariable logistic regression to predict the likelihood of upgrade for these patients. A nomogram was created using statistically significant variables. A corresponding formula was created to calculate the risk of upgrade. This risk was divided further into low, intermediate and high. A total of 57 (28.1%) cases had upgrade. A nomogram was created that included age, menopausal status, hormone therapy status, personal history of breast cancer, number of involved cores, solid growth pattern, size of largest focus and mammographic mass versus calcifications. The nomogram had an area under the receiver operating characteristic curve of 0.775. Conclusions We have developed a user-friendly nomogram that uses easily recognized variables to calculate the likelihood of upgrade for ADH. The nomogram could assist the treating surgeon in decision-making, particularly when the patient is at risk for surgical intervention. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
211. Inter-Institutional Pathology Consultation: The Importance of Breast Pathology Subspecialization in a Setting of Tertiary Cancer Center.
- Author
-
Soofi, Yousef and Khoury, Thaer
- Subjects
- *
BREAST tumor diagnosis , *THERAPEUTIC use of biochemical markers , *ACADEMIC medical centers , *ALGORITHMS , *BIOPSY , *BREAST diseases , *MEDICAL referrals , *QUALITY assurance , *LITERATURE reviews , *RETROSPECTIVE studies - Abstract
Inter-institutional pathology consultation (IPC) has shown to be significant in patient care. The purpose of the study was to evaluate the impact of IPC for breast biopsies in our institution. A total of 502 consecutive consult cases of breast core needle biopsies were reviewed. The original pathology reports from the referring institutions and our reports were compared for all cases. All cases were reviewed by specialized breast pathologists. Discordance was divided into minor and major based on the impact on patient care. We reviewed the subsequent excisional biopsy for all discordant cases. Discordance was seen in 104 (20.7%) cases; 40 (8%) had a major discordance and 64 (13%) had a minor discordance. Subsequent surgical excision was available for 25 (62.5%) cases with major discordance and for 13 (20.3%) with minor discordance. Our interpretation changed management in 15 (3%) patients, while 25 (5%) had a potential of management change. The cases with major discordance could be subcategorized into five groups, malignant 5 (12.5%), premalignant 16 (40%), biomarkers 10 (25%), fibroepithelial lesions 6 (15%), and others 3 (7.5%). Our findings support the value of IPC review in decreasing the likelihood of diagnostic errors that may lead to significant impact on patient care. It is necessary that outside pathology material in the referral settings been reviewed by a specialized breast pathologist. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
212. Variants of estrogen-related genes and breast cancer risk in European and African American women.
- Author
-
Lei Quan, Chi-Chen Hong, Zirpoli, Gary, Roberts, Michelle R., Khoury, Thaer, Sucheston-Campbell, Lara E., Bovbjerg, Dana H., Jandorf, Lina, Pawlish, Karen, Ciupak, Gregory, Davis, Warren, Bandera, Elisa V., Ambrosone, Christine B., and Song Yao
- Subjects
BREAST cancer risk factors ,ESTROGEN-related receptors ,GENETICS of breast cancer ,SINGLE nucleotide polymorphisms ,HORMONE therapy ,PHYSIOLOGY - Abstract
It has been observed previously that compared with women of European ancestry (EA), those of African ancestry (AA) are more likely to develop estrogen receptor (ER)-negative breast cancer, although the mechanisms have not been elucidated. We tested the associations between breast cancer risk and a targeted set of 20 genes known to be involved in estrogen synthesis, metabolism, and response and potential gene-environment interactions using data and samples from 1307 EA (658 cases) and 1365 AA (621 cases) participants from the Women's Circle of Health Study (WCHS). Multivariable logistic regression found evidence of associations with single-nucleotide polymorphisms (SNPs) in the ESR1 gene in EA women (rs1801132, odds ratio (OR)=1.47, 95% CI=1.20-1.80, P=0.0002; rs2046210, OR=1.24, 95% CI=1.04-1.47, P=0.02; and rs3020314, OR=1.43, 95% CI=1.19-1.70, P=0.00009), but not in AA women. The only other gene associated with breast cancer risk was CYP1A2 in AA women (rs2470893, OR=1.42, 95% CI=1.00-2.02, P=0.05), but not in EA women. When stratified by ER status, ESR1 rs1801132, rs2046210, and rs3020314 showed stronger associations in ER-positive than in ER-negative breast cancer in only EA women. Associations with the ESR1 SNPs in EA women also appeared to be stronger with longer endogenous estrogen exposure or hormonal replacement therapy use. Our results indicate that there may be differential genetic influences on breast cancer risk in EA compared with AA women and that these differences may be modified by tumor subtype and estrogen exposures. Future studies with a larger sample size may determine the full contribution of estrogen-related genes to racial/ethnic differences in breast cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
213. The Thoc1 Ribonucleoprotein and Prostate Cancer Progression.
- Author
-
Chinnam, Meenalakshmi, Wang, Yanqing, Xiaojing Zhang, Gold, David L., Khoury, Thaer, Yu Nikitin, Alexander, Foster, Barbara A., Yanping Li, Bshara, Wiam, Morrison, Carl D., Payne Ondracek, Rochelle D., Mohler, James L., and Goodrich, David W.
- Subjects
NUCLEOPROTEINS ,DIAGNOSIS ,PROSTATE cancer ,CANCER invasiveness ,BIOMARKERS ,IMMUNOSTAINING - Abstract
Background The majority of newly diagnosed prostate cancers will remain indolent, but distinguishing between aggressive and indolent disease is imprecise. This has led to the important clinical problem of overtreatment. THOC1 encodes a nuclear ribonucleoprotein whose expression is higher in some cancers than in normal tissue. The hypothesis that THOC1 may be a functionally relevant biomarker that can improve the identification of aggressive prostate cancer has not been tested. Methods THOC1 protein immunostaining was evaluated in a retrospective collection of more than 700 human prostate cancer specimens and the results associated with clinical variables and outcome. Thoc1 was conditionally deleted in an autochthonous mouse model (n = 22 or 23 per genotype) to test whether it is required for prostate cancer progression. All statistical tests were two-sided. Results THOC1 protein immunostaining increases with higher Gleason score and more advanced Tumor/Node/Metastasis stage. Time to biochemical recurrence is statistically significantly shorter for cancers with high THOC1 protein (log-rank P = .002, and it remains statistically significantly associated with biochemical recurrence after adjusting for Gleason score, clinical stage, and prostate-specific antigen levels (hazard ratio = 1.61, 95% confidence interval = 1.03 to 2.51, P = .04). Thoc1 deletion prevents prostate cancer progression in mice, but has little effect on normal tissue. Prostate cancer cells deprived of Thoc1 show gene expression defects that compromise cell growth. Conclusions Thoc1 is required to support the unique gene expression requirements of aggressive prostate cancer in mice. In humans, high THOC1 protein immunostaining associates with prostate cancer aggressiveness and recurrence. Thus, THOC1 protein is a functionally relevant molecular marker that may improve the identification of aggressive prostate cancers, potentially reducing overtreatment. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
214. COX-2 Expression in Hepatocellular Carcinoma is an Initiation Event; While EGF Receptor Expression with Downstream Pathway Activation is a Prognostic Predictor of Survival
- Author
-
Foster, Jason, primary, Black, Jennifer, additional, LeVea, Charles, additional, Khoury, Thaer, additional, Kuvshinoff, Boris, additional, Javle, Miland, additional, and Gibbs, John F., additional
- Published
- 2006
- Full Text
- View/download PDF
215. Intestinal Trefoil Factor [TFF-3] and Extracellular Signal Regulated Kinase [Erk] Expression in Pancreatic Cancer
- Author
-
Bhagat, Vishal K., primary, Khoury, Thaer, additional, Yu, Jihnhe, additional, and Javle, Milind, additional
- Published
- 2006
- Full Text
- View/download PDF
216. Inclusion of MUC1 (Ma695) in a panel of immunohistochemical markers is useful for distinguishing between endocervical and endometrial mucinous adenocarcinoma*
- Author
-
Khoury, Thaer, primary, Tan, Dongfeng, additional, Wang, Jianmin, additional, Intengan, Marilyn, additional, Yang, Jun, additional, Alrawi, Sadir, additional, Yan, Peisha, additional, and Byrd, James C, additional
- Published
- 2006
- Full Text
- View/download PDF
217. Malignant Glomus Tumor
- Author
-
Khoury, Thaer, primary, Balos, Lucia, additional, McGrath, Brian, additional, Wong, Michael K.K, additional, Cheney, Richard T, additional, and Tan, Dongfeng, additional
- Published
- 2005
- Full Text
- View/download PDF
218. EGFR Related Signaling Pathway Has Prognostic Significance in Cholangiocarcinoma
- Author
-
Chadha, Krishdeep S., primary, Khoury, Thaer, additional, LeVae, Charles, additional, Yu, Jihnhee, additional, and Javle, Milind, additional
- Published
- 2005
- Full Text
- View/download PDF
219. Activated AKT and ERK Expression May Predict Survival after Surgery in Pancreatic Carcinoma
- Author
-
Chadha, Krishdeep S., primary, Black, Jennifer, additional, Khoury, Thaer, additional, Gibbs, John, additional, Yu, Jihnhee, additional, LeVae, Charles, additional, and Javle, Milind M., additional
- Published
- 2005
- Full Text
- View/download PDF
220. Pathologic Quiz Case: An Asymptomatic 79-Year-Old Woman With an Abnormal Papanicolaou Test
- Author
-
Khoury, Thaer, primary, Lele, Shashi, additional, and Tan, Dongfeng, additional
- Published
- 2004
- Full Text
- View/download PDF
221. Lobular neoplasia detected in MRI-guided core biopsy carries a high risk for upgrade: a study of 63 cases from four different institutions
- Author
-
Khoury, Thaer, Kumar, Prasanna R, Li, Zaibo, Karabakhtsian, Rouzan G, Sanati, Souzan, Chen, Xiwei, Wang, Dan, Liu, Song, and Reig, Beatriu
- Abstract
There are certain criteria to recommend surgical excision for lobular neoplasia diagnosed in mammographically detected core biopsy. The aims of this study are to explore the rate of upgrade of lobular neoplasia detected in magnetic resonance imaging (MRI)-guided biopsy and to investigate the clinicopathological and radiological features that could predict upgrade. We reviewed 1655 MRI-guided core biopsies yielding 63 (4%) cases of lobular neoplasia. Key clinical features were recorded. MRI findings including mass vs non-mass enhancement and the reason for biopsy were also recorded. An upgrade was defined as the presence of invasive carcinoma or ductal carcinoma in situ in subsequent surgical excision. The overall rate of lobular neoplasia in MRI-guided core biopsy ranged from 2 to 7%, with an average of 4%. A total of 15 (24%) cases had an upgrade, including 5 cases of invasive carcinoma and 10 cases of ductal carcinoma in situ. Pure lobular neoplasia was identified in 34 cases, 11 (32%) of which had upgrade. In this group, an ipsilateral concurrent or past history of breast cancer was found to be associated with a higher risk of upgrade (6/11, 55%) than contralateral breast cancer (1 of 12, 8%; P=0.03). To our knowledge, this is the largest series of lobular neoplasia diagnosed in MRI-guided core biopsy. The incidence of lobular neoplasia is relatively low. Lobular neoplasia detected in MRI-guided biopsy carries a high risk for upgrade warranting surgical excision. However, more cases from different types of institutions are needed to verify our results.
- Published
- 2016
- Full Text
- View/download PDF
222. Parity and breastfeeding among African-American women: differential effects on breast cancer risk by estrogen receptor status in the Women's Circle of Health Study.
- Author
-
Ambrosone, Christine, Zirpoli, Gary, Ruszczyk, Melanie, Shankar, Jyoti, Hong, Chi-Chen, McIlwain, Demetra, Roberts, Michelle, Yao, Song, McCann, Susan, Ciupak, Gregory, Hwang, Helena, Khoury, Thaer, Jandorf, Lina, Bovbjerg, Dana, Pawlish, Karen, and Bandera, Elisa
- Abstract
Purpose: It has long been held that parity reduces risk of breast cancer. However, accumulating evidence indicates that the effects of parity, as well as breastfeeding, may vary according to estrogen receptor (ER) status. We evaluated these associations in a case-control study among African-American women in New York City and New Jersey. Methods: In the Women's Circle of Health Study, including 786 African-American women with breast cancer and 1,015 controls, data on reproductive histories were collected from in-person interviews, with tumor characteristics abstracted from pathology reports. We calculated number of live births and months breastfeeding for each child, and examined each in relation to breast cancer by ER status, and for triple-negative (TN) breast cancer. Results: Although associations were not statistically significant, having children was associated with reduced risk of ER+ breast cancer [odds ratio (OR) 0.82, 95 % confidence interval (CI) 0.58-1.16], but increased risk of ER− tumors, with associations most pronounced for TN breast cancer (OR 1.81, 95 % CI 0.93-3.51). Breastfeeding gave no additional benefit for ER+ cancer, but reduced the risk of ER− disease associated with parity. Conclusions: Accumulating data from a number of studies, as well as our own in African-American women, indicate that the effects of parity and breastfeeding differ by ER status. African-American women are more likely to have children and not to breastfeed, and to have ER− and TN breast cancer. It is possible that breastfeeding in this population could reduce risk of more aggressive breast cancers. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
223. Intracystic papillary carcinoma of breast: interrelationship with in situ and invasive carcinoma and a proposal of pathogenesis: array comparative genomic hybridization study of 14 cases.
- Author
-
Khoury, Thaer, Hu, Qiang, Liu, Song, and Wang, Jianmin
- Published
- 2014
- Full Text
- View/download PDF
224. Genetic variants in microRNAs and breast cancer risk in African American and European American women.
- Author
-
Yao, Song, Graham, Kelly, Shen, Jie, Campbell, Lara, Singh, Prashant, Zirpoli, Gary, Roberts, Michelle, Ciupak, Gregory, Davis, Warren, Hwang, Helena, Khoury, Thaer, Bovbjerg, Dana, Jandorf, Lina, Pawlish, Karen, Bandera, Elisa, Liu, Song, Ambrosone, Christine, and Zhao, Hua
- Abstract
MicroRNAs (miRNAs) are an integral part of the post-transcriptional machinery of gene expression and have been implicated in the carcinogenic cascade. Single nucleotide polymorphisms (SNPs) in miRNAs and risk of breast cancer have been evaluated in populations of European or Asian ancestry, but not among women of African ancestry. Here we examined 145 SNPs in six miRNA processing genes and in 78 miRNAs which target genes known to be important in breast cancer among 906 African American (AA) and 653 European American (EA) cases and controls enrolled in the Women's Circle of Health Study. Allele frequencies of most SNPs (87 %) differed significantly by race. We found a number of SNPs in miRNAs and processing genes in association with breast cancer overall or stratified by estrogen receptor (ER) status. Several associations were significantly different by race, with none of the associations being significant in both races. Using a polygenic risk score to combine the effects of multiple SNPs, we found significant associations with the score in each subgroup analysis. For ER-positive cancer, each unit increment of the risk score was associated with a 51 % increased risk in AAs (OR = 1.51, 95 % CI = 1.30-1.74, p = 3.3 × 10) and a 73 % increased risk in EAs (OR = 1.73, 95 % CI = 1.45-2.06, p = 1.4 × 10). These data show, for the first time, that miRNA-related genetic variations may underlie the etiology of breast cancer in both populations of African and European ancestries. Future studies are needed to validate our findings and to explore the underlying mechanisms. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
225. The Metastasis-Associated Gene MTA3, a Component of the Mi-2/NuRD Transcriptional Repression Complex, Predicts Prognosis of Gastroesophageal Junction Adenocarcinoma
- Author
-
Dong, Hongmei, Guo, Hong, Xie, Liangxi, Wang, Geng, Zhong, Xueyun, Khoury, Thaer, Tan, Dongfeng, and Zhang, Hao
- Subjects
METASTASIS ,GENETIC transcription ,ESOPHAGOGASTRIC junction ,ADENOCARCINOMA ,EPITHELIAL cells ,MESENCHYMAL stem cells ,PROGNOSIS - Abstract
Gastroesophageal junction (GEJ) adenocarcinoma carries a poor prognosis that is largely attributable to early and frequent metastasis. The acquisition of metastatic potential in cancer involves epithelial-to-mesenchymal transition (EMT). The metastasis-associated gene MTA3, a novel component of the Mi-2/NuRD transcriptional repression complex, was identified as master regulator of EMT through inhibition of Snail to increase E-cadherin expression in breast cancer. Here, we evaluated the expression pattern of the components of MTA3 pathway and the corresponding prognostic significance in GEJ adenocarcinoma. MTA3 expression was decreased at both protein and mRNA levels in tumor tissues compared to the non-tumorous and lowed MTA3 levels were noted in tumor cell lines with stronger metastatic potential. Immunohistochemical analysis of a cohort of 128 cases exhibited that patients with lower expression of MTA3 had poorer outcomes. Combined misexpression of MTA3, Snail and E-cadherin had stronger correlation with malignant properties. Collectively, results suggest that the MTA3-regulated EMT pathway is altered to favor EMT and, therefore, disease progression and that MTA3 expression was an independent prognostic factor in patients with GEJ adenocarcinoma. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
226. Foregut duplication cysts: A report of two cases with emphasis on embryogenesis.
- Author
-
Khoury, Thaer and Rivera, Louis
- Subjects
- *
GASTRIC diseases , *CYSTS (Pathology) , *EPITHELIUM , *TRANSCRIPTION factors , *PHENOTYPES , *EMBRYOLOGY - Abstract
Duplication cyst of the stomach with a pseudostratified columnar ciliated epithelium is extremely rare. We describe two cases of these cysts, with emphasis on their immunophenotype and embryogenesis. The first patient was a 29-year-old man who presented with cramping abdominal pain in his left lower quadrant. The second patient was a 26-year-old woman who had a history, over several years, of chronic epigastric abdominal pain radiating to her back. Both lesions were surgically removed. They showed the same histomorphology. The cysts were lined by a pseudostratified respiratory epithelium with ciliated cells. The first cyst was connected to the stomach, while the second cyst was not connected. Both cysts expressed thyroid transcription factor-1 (TTF-1) and surfactant. In this report, we explore the possible embryogenesis of these lesions in the light of TTF-1 and surfactant expression. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
227. Mammary Paget's disease and extra-mammary Paget's disease: two morphologically similar but biologically different diseases.
- Author
-
Weiguo Liu, Iqbal, Jabad, and Khoury, Thaer
- Subjects
EPIDERMAL growth factor ,SKIN cancer patients ,NIPPLE (Anatomy) ,VULVAR diseases ,PHOSPHOINOSITIDES ,DISEASES - Abstract
Background: The cells of origin of mammary Paget's disease (MPD) and extra-mammary Paget's disease (EMPD) have been a controversial subject. The purpose of this study is to examine the expression of the human epidermal growth factor receptor 2 (HER2) pathway members in these two diseases. Design: HER2, AKT, pAKT, PTEN, epidermal growth factor receptor (EGFR) and pEGFR were examined in 16 MPD and 14 EMPD cases. HER2 was graded on a scale from 0 to 3. A score of 3 was considered positive. For AKT, pAKT, PTEN, EGFR and pEGFR, a semi-quantitative scoring system was used. A score >100 was considered positive. Fisher's exact test was used to analyze the data. Results: HER2 was overexpressed in 87.5% MPD and 35.7% EMPD. While AKT was expressed in all cases, pAKT was expressed in 87.5% MPD and 92.9% EMPD. Both EGFR and pEGFR were negative in all cases. PTEN was positive in 62.5% MPD and 71.4% EMPD. For pAKT+ group, HER2–/PTEN+ was recorded in 0% MPD and 38.5% EMPD ( P = .01). Conclusions: In a subset of EMPD, AKT is not activated by HER2 overexpression or by loss of PTEN, which is not the case in MPD. These data suggest that these two diseases are biologically different. Liu W, Iqbal J, Khoury T. Mammary Paget's disease and extramammary Paget's disease: two morphologically similar but biologically different diseases. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
228. Effect of Delayed Formalin Fixation on Estrogen and Progesterone Receptors in Breast Cancer.
- Author
-
Jingxin Qiu, Kulkarni, Swati, Chandrasekhar, Rameela, Rees, Mark, Hyde, Kathryn, Wilding, Gregory, Dongfeng Tan, and Khoury, Thaer
- Subjects
ESTROGEN receptors ,PROGESTERONE receptors ,BREAST cancer ,IMMUNOGLOBULINS ,HORMONE receptors - Abstract
We previously reported that delayed formalin fixation (DFF) has a negative effect on immunohistochemical staining of estrogen receptor (ER), progesterone receptor (PR), and HER2. The primary aim of the study was to determine if DFF affected commonly used clones of the ER and PR differentially. The specific clones evaluated were ER clones 1D5, 6F11, and SP1 and PR clones 16, 1E2, and PgR636. Ten breast cancer cases were dissected and fixed at different times (0, 10, and 30 minutes; 1, 2, 4, and 8 hours; and overnight) and were then stained with anti-ER and anti-PR antibodies. The mean Q score for ER started to decline at 2 to 4 hours for clones 1D5 and 6F11 and at 1 hour for SP1. SP1 was superior to 1D5 at the 8-hour mark (P = .03). The Q score for PR started to decline at 1 hour for clones PgR636 and 16 and 4 to 8 hours for 1E2 (P = .03). Based on our findings, it appears that regardless of the antibody clones evaluated, DFF has a negative effect on hormone receptors. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
229. CSPG4 Protein as a New Target for the Antibody-Based Immunotherapy of Triple-Negative Breast Cancer.
- Author
-
Xinhui Wang, Osada, Takuya, Yangyang Wang, Ling Yu, Sakakura, Koichi, Katayama, Akihiro, McCarthy, James B., Brufsky, Adam, Chivukula, Mamatha, Khoury, Thaer, Hsu, David S., Barry, William T., Lyerly, H. Kim, Clay, Timothy M., and Ferrone, Soldano
- Subjects
IMMUNOTHERAPY ,CHONDROITIN sulfates ,MONOCLONAL antibodies ,TRIPLE-negative breast cancer ,CANCER patients ,REGRESSION analysis ,CELL proliferation - Abstract
Background The cell surface proteoglycan, chondroitin sulfate proteoglycan 4 (CSPG4), is a potential target for monoclonal antibody (mAb)–based immunotherapy for many types of cancer. The lack of effective therapy for triple-negative breast cancer (TNBC) prompted us to examine whether CSPG4 is expressed in TNBC and can be targeted with CSPG4-specific mAb. Methods CSPG4 protein expression was assessed in 44 primary TNBC lesions, in TNBC cell lines HS578T, MDA-MB-231, MDA-MB-435, and SUM149, and in tumor cells in pleural effusions from 12 metastatic breast cancer patients. The effect of CSPG4-specific mAb 225.28 on growth, adhesion, and migration of TNBC cells was tested in vitro. The ability of mAb 225.28 to induce regression of tumor metastases (n = 7 mice) and to inhibit spontaneous metastasis and tumor recurrence (n = 12 mice per group) was tested in breast cancer models in mice. The mechanisms responsible for the antitumor effect of mAb 225.28 were also investigated in the cell lines and in the mouse models. All statistical tests were two-sided. Results CSPG4 protein was preferentially expressed in 32 of the 44 (72.7%) primary TNBC lesions tested, in TNBC cell lines, and in tumor cells in pleural effusions from 12 metastatic breast cancer patients. CSPG4-specific mAb 225.28 statistically significantly inhibited growth, adhesion, and migration of TNBC cells in vitro. mAb 225.28 induced 73.1% regression of tumor metastasis in a TNBC cell–derived experimental lung metastasis model (mAb 225.28 vs control, mean area of metastatic nodules = 44590.8 vs 165950.8 μm2; difference of mean = 121360.0 μm2, 95% confidence interval = 91010.7 to 151709.4 μm2; P < .001). Additionally, mAb 225.28 statistically significantly reduced spontaneous lung metastases and tumor recurrences in an orthotopic xenograft mouse model. The mechanisms responsible for antitumor effect included increased apoptosis and reduced mitotic activity in tumor cells, decreased blood vessel density in the tumor microenvironment, and reduced activation of signaling pathways involved in cell survival, proliferation and metastasis. Conclusions This study identified CSPG4 as a new target for TNBC. The antitumor activity of CSPG4-specific mAb was mediated by multiple mechanisms, including the inhibition of signaling pathways crucial for TNBC cell survival, proliferation, and metastasis. [ABSTRACT FROM PUBLISHER]
- Published
- 2010
- Full Text
- View/download PDF
230. The expression of TRMT2A, a novel cell cycleregulated protein, identifies a subset of breastcancer patients with HER2 over-expression thatare at an increased risk of recurrence.
- Author
-
Hicks, David G., Janarthanan, Bagi R., Vardarajan, Ramya, Kulkarni, Swati A., Khoury, Thaer, Dim, Daniel, Budd, G. Thomas, Yoder, Brian J., Tubbs, Raymond, Schreeder, Marshall T., Estopinal, Noel C., Beck, Rodney A., Yanling Wang, Ring, Brian Z., Seitz, Robert S., and Ross, Douglas T.
- Subjects
CANCER patients ,BREAST cancer ,CANCER treatment ,DRUG therapy ,CELL cycle regulation - Abstract
Background: Over-expression of HER2 in a subset of breast cancers (HER2+) is associated with high histological grade and aggressive clinical course. Despite these distinctive features, the differences in response of HER2+ patients to both adjuvant cytotoxic chemotherapy and targeted therapy (e.g. trastuzumab) suggests that unrecognized biologic and clinical diversity is confounding treatment strategies. Furthermore, the small but established risk of cardiac morbidity with trastuzumab therapy compels efforts towards the identification of biomarkers that might help stratify patients. Methods: A single institution tissue array cohort assembled at the Clearview Cancer Institute of Huntsville (CCIH) was screened by immunohistochemistry staining using a large number of novel and commercially available antibodies to identify those with a univariate association with clinical outcome in HER2+ patients. Staining with antibody directed at TRMT2A was found to be strongly associated with outcome in HER2+ patients. This association with outcome was tested in two independent validation cohorts; an existing staining dataset derived from tissue assembled at the Cleveland Clinic Foundation (CCF), and in a new retrospective study performed by staining archived paraffin blocks available at the Roswell Park Cancer Institute (RPCI). Results: TRMT2A staining showed a strong correlation with likelihood of recurrence at five years in 67 HER2+ patients from the CCIH discovery cohort (HR 7.0; 95% CI 2.4 to 20.1, p < 0.0004). This association with outcome was confirmed using 75 HER2+ patients from the CCF cohort (HR 3.6; 95% CI 1.3 to 10.2, p < 0.02) and 64 patients from the RPCI cohort (HR 3.4; 95% CI 1.3-8.9, p < 0.02). In bivariable analysis the association with outcome was independent of grade, tumor size, nodal status and the administration of conventional adjuvant chemotherapy in the CCIH and RPCI cohorts. Conclusions: Studies from three independent single institution cohorts support TRMT2A protein expression as a biomarker of increased risk of recurrence in HER2+ breast cancer patients. These results suggest that TRMT2A expression should be further studied in the clinical trial setting to explore its predictive power for response to adjuvant cytotoxic chemotherapy in combination with HER2 targeted therapy. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
231. Intracystic papillary carcinoma of breast: interrelationship with in situand invasive carcinoma and a proposal of pathogenesis: array comparative genomic hybridization study of 14 cases
- Author
-
Khoury, Thaer, Hu, Qiang, Liu, Song, and Wang, Jianmin
- Abstract
Classifying intracystic papillary carcinoma under invasive or in situductal carcinoma is still a matter of debate. The purpose of this study was to explore the genomic relationship of this tumor to its concurrent invasive ductal carcinoma and ductal carcinoma in situusing array comparative genomic hybridization. Intracystic papillary carcinoma cases were classified into three categories: pure, with concurrent ductal carcinoma in situor with concurrent invasive ductal carcinoma. Each component was dissected using laser capture microdissection. DNA was extracted and array comparative genomic hybridization was performed. The test of difference in copy number changes among the three tumors was carried out using CGHMultiArray. Intracystic papillary carcinoma clustered with four of five concurrent ductal carcinoma in situcases and with two of two invasive ductal carcinoma cases. Intracystic papillary carcinoma showed the highest proportions of genome copy number aberration, followed by ductal carcinoma in situ, and then by invasive ductal carcinoma (P=0.06). Comparing intracystic papillary carcinoma with invasive ductal carcinoma vswithout invasive ductal carcinoma, the former had 11q22.1–23.3 loss (P=0.031) and chr5 gain (P=0.085), and was enriched with matrix metalloproteinase genes. Comparing intracystic papillary carcinoma with ductal carcinoma in situ vswithout ductal carcinoma in situ, the former had gain in 5q35.3 (P=0.041), 8q24.3 (P=0.041) and 21q13.2 to 21q13.31 (P=0.011). Comparing intracystic papillary carcinoma with ductal carcinoma in situ, the latter acquired a group of genes involved in cell adhesion and motility, whereas intracystic papillary carcinoma differentially expressed genes that are involved in papillary carcinomas of other organs (thyroid and kidney). We conclude that the overall molecular change in intracystic papillary carcinoma is closer to ductal carcinoma in situthan to invasive ductal carcinoma, which may explain the indolent behavior of this tumor. We offer herein a proposal of intracystic papillary carcinoma pathogenesis through its relation to invasive ductal carcinoma and ductal carcinoma in situ.
- Published
- 2014
- Full Text
- View/download PDF
232. Best practices for achieving consensus in HER2‐low expression in breast cancer: current perspectives from practising pathologists.
- Author
-
Tozbikian, Gary, Bui, Marilyn M., Hicks, David G, Jaffer, Shabnam, Khoury, Thaer, Wen, Hannah Y, Krishnamurthy, Savitri, and Wei, Shi
- Subjects
- *
PROTEIN overexpression , *BREAST cancer , *BIOMARKERS , *PATHOLOGISTS , *BEST practices , *EPIDERMAL growth factor receptors - Abstract
Aims: Human epidermal growth factor receptor 2 (HER2) expression is an important biomarker in breast cancer (BC). Most BC cases categorised as HER2‐negative (HER2−) express low levels of HER2 [immunohistochemistry (IHC) 1+ or IHC 2+/in‐situ hybridisation not amplified (ISH−)] and represent a clinically relevant therapeutic category that is amenable to targeted therapy using a recently approved HER2‐directed antibody–drug conjugate. A group of practising pathologists, with expertise in breast pathology and BC biomarker testing, outline best practices and guidance for achieving consensus in HER2 IHC scoring for BC. Methods and results: The authors describe current knowledge and challenges of IHC testing and scoring of HER2‐low expressing BC and provide best practices and guidance for accurate identification of BCs expressing low levels of HER2. These expert pathologists propose an algorithm for assessing HER2 expression with validated IHC assays and incorporate the 2023 American Society of Clinical Oncology and College of American Pathologist guideline update. The authors also provide guidance on when to seek consensus for HER2 IHC scoring, how to incorporate HER2‐low into IHC reporting and present examples of HER2 IHC staining, including challenging cases. Conclusions: Awareness of BC cases that are negative for HER protein overexpression/gene amplification and the related clinical relevance for targeted therapy highlight the importance of accurate HER2 IHC scoring for optimal treatment selection. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
233. Body fatness and mTOR pathway activation of breast cancer in the Women's Circle of Health Study.
- Author
-
Cheng, Ting-Yuan David, Omilian, Angela R., Yao, Song, Sanchez, Pamela V., Polk, Latasia Z., Zhang, Weizhou, Datta, Susmita, Bshara, Wiam, Ondracek, Rochelle Payne, Davis, Warren, Liu, Song, Hong, Chi-Chen, Bandera, Elisa V., Khoury, Thaer, and Ambrosone, Christine B.
- Published
- 2020
- Full Text
- View/download PDF
234. Metaplastic Carcinoma Revisited; Subtypes Determine Outcomes
- Author
-
Khoury, Thaer
- Abstract
Metaplastic breast carcinoma (MpBC) is a heterogeneous group of tumors that clinically could be divided into low risk and high risk. It is important to recognize the different types of MpBC, as the high-risk subtypes have worse clinical outcomes than triple-negative breast cancer. It is important for the pathologist to be aware of the MpBC entities and use the proposed algorithms (morphology and immunohistochemistry) to assist in rendering the final diagnosis. Few pitfalls are discussed, including misinterpretation of immunohistochemistry and certain histomorphologies, particularly spindle lesions associated with complex sclerosing lesions.
- Published
- 2021
- Full Text
- View/download PDF
235. Genome-wide association study identifies 25 known breast cancer susceptibility loci as risk factors for triple-negative breast cancer
- Author
-
Pontificia Universidad Javeriana. Facultad de Medicina. Instituto de Genética Humana, Purrington, Kristen S., Slager, Susan, Yannoukakos, Drakoulis, Fasching, Peter A., Miron, Penelope, Carpenter, Jane, Chang-Claude, Jenny, Martin, Nicholas G., Montgomery, Grant W., Anton-Culver, Hoda, Goodfellow, Paul, Tapper, William J., Rafiq, Sajjad, Gerty, Susan M., Durcan, Lorraine, Konstantopoulou, Irene, Fostira, Florentia, Vratimos, Athanassios, Apostolou, Paraskevi, Konstanta, Irene, Kotoula, Vassiliki, Lakis, Sotiris, Dimopoulos, Meletios A., Skarlos, Dimosthenis, Fountzilas, George, Beckmann, Matthias W., Hein, Alexander, Ruebner, Matthias, Ekici, Arif B., Hartmann, Arndt, Schulz-Wendtland, Ruediger, Renner, Stefan P., Janni, Wolfgang, Rack, Brigitte, Scholz, Christoph, Neugebauer, Julia, Andergassen, Ulrich, Lux, Michael P., Haeberle, Lothar, Clarke, Christine, Pathmanathan, Nirmala, Rudolph, Anja, Flesch-Janys, Dieter, Nickels, Stefan, Olson, Janet E., Ingle, James N., Olswold, Curtis, Slettedahl, Seth, Eckel-Passow, Jeanette E., Anderson, S. Keith, Visscher, Daniel W., Cafourek, Victoria L., Sicotte, Hugues, Prodduturi, Naresh, Weiderpass, Elisabete, Bernstein, Leslie, Ziogas, Argyrios, Ivanovich, Jennifer, Giles, Graham G., Baglietto, Laura, Southey, Melissa, Kosma, Veli-Matti, Fischer, Hans-Peter, Reed, Malcom W. R., Cross, Simon S., Deming-Halverson, Sandra, Shrubsole, Martha, Cai, Qiuyin, Shu, Xiao-Ou, Daly, Mary, Weaver, JoEllen, Ross, Eric, Klemp, Jennifer, Sharma, Priyanka, Torres, Diana, Rudiger, Thomas, Wolfing, Heidrun, Ulmer, Hans-Ulrich, Forsti, Asta, Khoury, Thaer, Kumar, Shicha, Pilarski, Robert, Shapiro, Charles L., Greco, Dario, Heikkila, Paivi, Aittomaki, Kristiina, Blomqvist, Carl, Irwanto, Astrid, Liu, Jianjun, Pankratz, Vernon Shane, Wang, Xianshu, Severi, Gianluca, Mannermaa, Arto, Easton, Douglas, Hall, Per, Brauch, Hiltrud, Cox, Angela, Zheng, Wei, Godwin, Andrew K., Hamann, Ute, Ambrosone, Christine, Toland, Amanda Ewart, Nevanlinna, Heli, Vachon, Celine M., Couch, Fergus J, Shu, Xiao Ou, Pontificia Universidad Javeriana. Facultad de Medicina. Instituto de Genética Humana, Purrington, Kristen S., Slager, Susan, Yannoukakos, Drakoulis, Fasching, Peter A., Miron, Penelope, Carpenter, Jane, Chang-Claude, Jenny, Martin, Nicholas G., Montgomery, Grant W., Anton-Culver, Hoda, Goodfellow, Paul, Tapper, William J., Rafiq, Sajjad, Gerty, Susan M., Durcan, Lorraine, Konstantopoulou, Irene, Fostira, Florentia, Vratimos, Athanassios, Apostolou, Paraskevi, Konstanta, Irene, Kotoula, Vassiliki, Lakis, Sotiris, Dimopoulos, Meletios A., Skarlos, Dimosthenis, Fountzilas, George, Beckmann, Matthias W., Hein, Alexander, Ruebner, Matthias, Ekici, Arif B., Hartmann, Arndt, Schulz-Wendtland, Ruediger, Renner, Stefan P., Janni, Wolfgang, Rack, Brigitte, Scholz, Christoph, Neugebauer, Julia, Andergassen, Ulrich, Lux, Michael P., Haeberle, Lothar, Clarke, Christine, Pathmanathan, Nirmala, Rudolph, Anja, Flesch-Janys, Dieter, Nickels, Stefan, Olson, Janet E., Ingle, James N., Olswold, Curtis, Slettedahl, Seth, Eckel-Passow, Jeanette E., Anderson, S. Keith, Visscher, Daniel W., Cafourek, Victoria L., Sicotte, Hugues, Prodduturi, Naresh, Weiderpass, Elisabete, Bernstein, Leslie, Ziogas, Argyrios, Ivanovich, Jennifer, Giles, Graham G., Baglietto, Laura, Southey, Melissa, Kosma, Veli-Matti, Fischer, Hans-Peter, Reed, Malcom W. R., Cross, Simon S., Deming-Halverson, Sandra, Shrubsole, Martha, Cai, Qiuyin, Shu, Xiao-Ou, Daly, Mary, Weaver, JoEllen, Ross, Eric, Klemp, Jennifer, Sharma, Priyanka, Torres, Diana, Rudiger, Thomas, Wolfing, Heidrun, Ulmer, Hans-Ulrich, Forsti, Asta, Khoury, Thaer, Kumar, Shicha, Pilarski, Robert, Shapiro, Charles L., Greco, Dario, Heikkila, Paivi, Aittomaki, Kristiina, Blomqvist, Carl, Irwanto, Astrid, Liu, Jianjun, Pankratz, Vernon Shane, Wang, Xianshu, Severi, Gianluca, Mannermaa, Arto, Easton, Douglas, Hall, Per, Brauch, Hiltrud, Cox, Angela, Zheng, Wei, Godwin, Andrew K., Hamann, Ute, Ambrosone, Christine, Toland, Amanda Ewart, Nevanlinna, Heli, Vachon, Celine M., Couch, Fergus J, and Shu, Xiao Ou
236. Emerging Landscape of Targeted Therapy of Breast Cancers With Low Human Epidermal Growth Factor Receptor 2 Protein Expression.
- Author
-
Tozbikian, Gary, Krishnamurthy, Savitri, Bui, Marilyn M., Feldman, Michael, Hicks, David G., Jaffer, Shabnam, Khoury, Thaer, Shi Wei, Wen, Hannah, and Pohlmann, Paula
- Subjects
- *
IMMUNOHISTOCHEMISTRY , *EPIDERMAL growth factor receptors , *GENE expression , *PROTEOMICS , *GENE amplification , *BREAST tumors - Abstract
Context.-- Human epidermal growth factor receptor 2 (HER2) status in breast cancer is currently classified as negative or positive for selecting patients for anti-HER2 targeted therapy. The evolution of the HER2 status has included a new HER2-low category defined as an HER2 immunohistochemistry score of 1+ or 2+ without gene amplification. This new category opens the door to a targetable HER2-low breast cancer population for which new treatments may be effective. Objective.-- To review the current literature on the emerging category of breast cancers with low HER2 protein expression, including the clinical, histopathologic, and molecular features, and outline the clinical trials and best practice recommendations for identifying HER2-low-expressing breast cancers by immunohistochemistry. Data sources.-- We conducted a literature review based on peer-reviewed original articles, review articles, regulatory communications, ongoing and past clinical trials identified through ClinicalTrials.gov, and the authors' practice experience. Conclusions.-- The availability of new targeted therapy potentially effective for patients with breast cancers with low HER2 protein expression requires multidisciplinary recognition. In particular, pathologists need to recognize and identify this category to allow the optimal selection of patients for targeted therapy. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
237. Insulin use, adipokine profiles and breast cancer prognosis.
- Author
-
Wintrob, Zachary A.P., Hammel, Jeffrey P., Khoury, Thaer, Nimako, George K., Fu, Hsin-Wei, Fayazi, Zahra S., Gaile, Dan P., Forrest, Alan, and Ceacareanu, Alice C.
- Subjects
- *
TYPE 2 diabetes , *BODY mass index , *CYTOKINES , *TUMORS , *BREAST cancer - Abstract
Background Type-2 diabetes mellitus (T2DM) and breast cancer (BC) share common cytokine signaling changes resultant from adipose tissue dysfunction. This modified adipokine signaling was shown to be directly associated with changes in the body mass index (BMI) and diet and it is expected to also be influenced by T2DM pharmacotherapy. We evaluated the relationship between pre-existing diabetes treatment, circulating adipokine levels at cancer diagnosis, and long-term outcomes. Methods All incident BC cases were reviewed (01/01/2003-12/31/2009, N = 2194). Each of the subjects with baseline T2DM (cases) was matched with two other subjects without T2DM (controls) based on the following criteria: age, BMI, ethnicity, menopausal status and tumor stage. All cases and controls with available baseline plasma and tumor biopsies, and being surgery and BC treatment naïve, were included (N 1 = 97, N 2 = 194). Clinical history and vital status were documented. Adipokine levels (adiponectin, leptin, TNF-α, CRP, IL-1β, IL-1Ra, IL-6, and C-peptide) were assessed by either ELISA or Luminex® assays. Cancer outcomes were assessed by Kaplan-Meier analysis; associations between categorical variables were assessed by Fisher’s exact test, categorical and continuous variables by Kruskal-Wallis or Wilcoxon Rank-Sum test, where appropriate. Multivariate adjustments (MVP, multivariate p-value) were performed accounting for age, tumor stage, BMI, estrogen receptor (ER) status and cumulative comorbidity. All biomarker correlations were assessed by the Pearson method. Utilization of insulin and insulin secretagogues was associated with ER (−) phenotype (p = 0.008, p = 0.043) and poorer BC outcomes (p = 0.012, p = 0.033). Insulin users were found to have lower C-peptide and higher IL-6, TNF-α and CRP levels, of which elevated CRP and TNF-α were associated with poorer BC outcomes (p = 0.003, MVP = 0.210). Insulin remarked by higher leptin levels as compared to controls (p = 0.052), but did not differ significantly from non-users. Although lower adiponectin levels were observed among non-insulin users as compared to controls (p < 0.001, MVP = 0.006), insulin use seemed to have restored adiponectin production. C-peptide levels were lower among insulin users as compared to non-users (p < 0.001, MVP < 0.001) and approached levels comparable with those of the controls. In the overall dataset, C-peptide lower than 0.75 ng/ml were strongly associated with poorer survival (p = 0.007, MVP = 0.002). Among insulin users, C-peptide levels were inversely correlated with IL-1β and IL-1Ra levels only after full adjustment (p = 0.012, p = 0.030); the correlation was unremarkable in other groups. Conclusion Insulin use is associated with elevated leptin, CRP, TNFα, and lower C-peptide and also linked to poor BC outcomes. More research is needed to verify these findings; however, we are among the first to correlate pharmacotherapy use, measures of adipose tissue dysfunction and cancer outcomes. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
238. An epigenome-wide analysis of socioeconomic position and tumor DNA methylation in breast cancer patients.
- Author
-
Chen, Jianhong, Long, Mark D., Sribenja, Sirinapa, Ma, Sung Jun, Yan, Li, Hu, Qiang, Liu, Song, Khoury, Thaer, Hong, Chi-Chen, Bandera, Elisa, Singh, Anurag K., Repasky, Elizabeth A., Bouchard, Elizabeth G., Higgins, Michael, Ambrosone, Christine B., and Yao, Song
- Subjects
- *
DNA methylation , *METHYLATION , *INCOME , *CANCER patients , *BREAST cancer , *PROMOTERS (Genetics) - Abstract
Background: Disadvantaged socioeconomic position (SEP), including lower educational attainment and household income, may influence cancer risk and outcomes. We hypothesized that DNA methylation could function as an intermediary epigenetic mechanism that internalizes and reflects the biological impact of SEP. Methods: Based on tumor DNA methylation data from the Illumina 450 K array from 694 breast cancer patients in the Women's Circle of Health Study, we conducted an epigenome-wide analysis in relation to educational attainment and household income. Functional impact of the identified CpG sites was explored in silico using data from publicly available databases. Results: We identified 25 CpG sites associated with household income at an array-wide significance level, but none with educational attainment. Two of the top CpG sites, cg00452016 and cg01667837, were in promoter regions of NNT and GPR37, respectively, with multiple epigenetic regulatory features identified in each region. NNT is involved in β-adrenergic stress signaling and inflammatory responses, whereas GPR37 is involved in neurological and immune responses. For both loci, gene expression was inversely correlated to the levels of DNA methylation. The associations were consistent between Black and White women and did not differ by tumor estrogen receptor (ER) status. Conclusions: In a large breast cancer patient population, we discovered evidence of the significant biological impact of household income on the tumor DNA methylome, including genes in the β-adrenergic stress and immune response pathways. Our findings support biological effects of socioeconomic status on tumor tissues, which might be relevant to cancer development and progression. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
239. Results and lessons from dual extraction of DNA and RNA from formalin-fixed paraffin-embedded breast tumor tissues for a large Cancer epidemiologic study.
- Author
-
Ondracek, Rochelle Payne, Chen, Jianhong, Marosy, Beth, Szewczyk, Sirinapa, Medico, Leonard, Mohan, Amrutha Sherly, Nair, Priya, Pratt, Rachel, Roh, Janise M., Khoury, Thaer, Carpten, John, Kushi, Lawrence H., Palmer, Julie R., Doheny, Kim, Davis, Warren, Higgins, Michael J., Yao, Song, and Ambrosone, Christine B.
- Subjects
- *
BREAST tumors , *DNA , *RNA , *DNA methylation , *RNA methylation , *PROTEINASES - Abstract
Background: The use of archived formalin-fixed paraffin-embedded (FFPE) tumor tissues has become a common practice in clinical and epidemiologic genetic research. Simultaneous extraction of DNA and RNA from FFPE tissues is appealing but can be practically challenging. Here we report our results and lessons learned from processing FFPE breast tumor tissues for a large epidemiologic study. Methods: Qiagen AllPrep DNA/RNA FFPE kit was adapted for dual extraction using tissue punches or sections from breast tumor tissues. The yield was quantified using Qubit and fragmentation analysis by Agilent Bioanalyzer. A subset of the DNA samples were used for genome-wide DNA methylation assays and RNA samples for sequencing. The QC metrices and performance of the assays were analyzed with pre-analytical variables. Results: A total of 1859 FFPE breast tumor tissues were processed. We found it critical to adjust proteinase K digestion time based on tissue volume to achieve balanced yields of DNA and RNA. Tissue punches taken from tumor-enriched regions provided the most reliable output. A median of 1475 ng DNA and 1786 ng RNA per sample was generated. The median DNA integrity number (DIN) was 3.8 and median DV200 for RNA was 33.2. Of 1294 DNA samples used in DNA methylation assays, 97% passed quality check by qPCR and 92% generated data deemed high quality. Of the 130 RNA samples with DV200 ≥ 20% used in RNA-sequencing, all but 5 generated usable transcriptomic data with a mapping rate ≥ 60%. Conclusions: Dual DNA/RNA purification using Qiagen AllPrep FFPE extraction protocol is feasible for clinical and epidemiologic studies. We recommend tissue punches as a reliable source material and fine tuning of proteinase K digestion time based on tissue volume. Impact: Our protocol and recommendations may be adapted by future studies for successful extraction of archived tumor tissues. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
240. Pan-Cancer Characterization of Intratumoral Autonomic Innervation in 32 Cancer Types in the Cancer Genome Atlas.
- Author
-
Zhang, Jeff F., Sheng, Haiyang, Chen, Jianhong, Mohammadpour, Hemn, Ma, Sung Jun, Farrugia, Mark K., Gandhi, Shipra, Bouchard, Elizabeth G., Singh, Anurag K., Repasky, Elizabeth A., Khoury, Thaer, Ambrosone, Christine B., and Yao, Song
- Subjects
- *
AUTONOMIC nervous system , *CELLULAR signal transduction , *GENE expression profiling , *PATHOLOGIC neovascularization , *TUMOR markers , *TUMORS - Abstract
Simple Summary: There have been growing interests in the roles of intratumoral innervation of the autonomic nervous system (ANS) as a mechanism linking psychosocial stress, β-adrenergic signaling pathways, and poor cancer outcomes, and a potential target for therapeutic purpose. Our current knowledge is being limited by the few cancer types where intratumoral ANS have been studied; it remains to be determined the extent of this mechanism existing in different cancer types. Our study provided the first pan-cancer characterization of intratumoral innervation across 32 cancer types, and further, their relationships with tumor histopathological and molecular characteristics and survival outcomes. We found wide variations in intratumoral ANS expression both within and across cancer types. The association of ANS signatures with tumor histopathological characteristics and survival outcomes also varied by cancer type. Our findings suggest that the potential benefits of cancer therapies targeting β-adrenergic receptor-mediated stress signaling pathways are likely dependent on cancer type. Over the past two decades, multiple studies have demonstrated the important role that the autonomic nervous system (ANS) plays in tumorigenesis and cancer progression. However, the mechanisms by which this process occurs have only recently begun to be elucidated. Further, the extent of autonomic innervation in various cancer types and its effects on tumor molecular, immunological, and histopathological features, as well as on patient outcomes, are not yet fully characterized. In this study, we analyzed intratumoral ANS gene expression signatures, including overall intratumoral neuron growth and sympathetic and parasympathetic markers, across 32 cancer types using tumor transcriptomic and clinical annotation data available from The Cancer Genome Atlas (TCGA). Our analysis revealed wide variations in intratumoral ANS expression both within and across cancer types. The association of ANS signatures with tumor histopathological characteristics and survival outcomes also varied by cancer type. We found intratumoral ANS expression to be commonly correlated with angiogenesis, TGF-β signaling, and immunosuppression in the tumor microenvironment of many cancer types, which provide mechanistic insights into the involvement of intratumoral innervation in cancer development and progression. Our findings suggest that the potential benefits of cancer therapies targeting β-adrenergic receptor-mediated stress signaling pathways are likely dependent on cancer type. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
241. Identification of Glandular (Acinar)/Tubule Formation in Invasive Carcinoma of the Breast: A Study to Determine Concordance Using the World Health Organization Definition.
- Author
-
Lo Y, Lester SC, Ellis IO, Lanjewar S, Laurini J, Patel A, Bhattarai A, Ustun B, Harmon B, Kleer CG, Ross D, Amin A, Wang Y, Bradley R, Turashvili G, Zeng J, Baum J, Singh K, Hakima L, Harigopal M, Komforti M, Shin SJ, Abbott SE, Jaffer S, Badve SS, Khoury T, D'Alfonso TM, Ginter PS, Collins V, Towne W, Gan Y, Nassar A, Sahin AA, Flieder A, Aldrees R, Ngo MH, Edema U, Sapna F, Schnitt SJ, and Fineberg SA
- Subjects
- Humans, Female, Pathologists, Observer Variation, Neoplasm Grading, Breast Neoplasms pathology, Breast Neoplasms diagnosis, World Health Organization
- Abstract
Context.—: The Nottingham Grading System (NGS) developed by Elston and Ellis is used to grade invasive breast cancer (IBC). Glandular (acinar)/tubule formation is a component of NGS., Objective.—: To investigate the ability of pathologists to identify individual structures that should be classified as glandular (acinar)/tubule formation., Design.—: A total of 58 hematoxylin-eosin photographic images of IBC with 1 structure circled were classified as tubules (41 cases) or nontubules (17 cases) by Professor Ellis. Images were sent as a PowerPoint (Microsoft) file to breast pathologists, who were provided with the World Health Organization definition of a tubule and asked to determine if a circled structure represented a tubule., Results.—: Among 35 pathologists, the κ statistic for assessing agreement in evaluating the 58 images was 0.324 (95% CI, 0.314-0.335). The median concordance rate between a participating pathologist and Professor Ellis was 94.1% for evaluating 17 nontubule cases and 53.7% for 41 tubule cases. A total of 41% of the tubule cases were classified correctly by less than 50% of pathologists. Structures classified as tubules by Professor Ellis but often not recognized as tubules by pathologists included glands with complex architecture, mucinous carcinoma, and the "inverted tubule" pattern of micropapillary carcinoma. A total of 80% of participants reported that they did not have clarity on what represented a tubule., Conclusions.—: We identified structures that should be included as tubules but that were not readily identified by pathologists. Greater concordance for identification of tubules might be obtained by providing more detailed images and descriptions of the types of structures included as tubules., Competing Interests: The authors have no relevant financial interest in the products or companies described in this article., (© 2024 College of American Pathologists.)
- Published
- 2024
- Full Text
- View/download PDF
242. Infiltration of Common Myeloid Progenitor (CMP) Cells is Associated With Less Aggressive Tumor Biology, Lower Risk of Brain Metastasis, Better Response to Immunotherapy, and Higher Patient Survival in Breast Cancer.
- Author
-
Oshi M, Wu R, Khoury T, Gandhi S, Yan L, Yamada A, Ishikawa T, Endo I, and Takabe K
- Subjects
- Humans, Female, Myeloid Progenitor Cells metabolism, Myeloid Progenitor Cells pathology, Middle Aged, Brain Neoplasms therapy, Brain Neoplasms secondary, Tumor Microenvironment, Breast Neoplasms pathology, Breast Neoplasms therapy, Breast Neoplasms mortality, Immunotherapy methods
- Abstract
Objective: To investigate the clinical relevance of common myeloid progenitor (CMP) cells in breast tumor microenvironment (TME)., Background: The role of rare cells in TME is less studied. In Silico transcriptomic analyses of real-world data enable us to detect and quantify rare cells, including CMP cells., Methods: A total of 5176 breast cancer (BC) patients from SCAN-B, METABRIC, and 5 single-cell sequence cohorts were analyzed using the xCell algorithm. The high group was defined as more than two-thirds of the CMP scores in each cohort., Results: CMP cells consist of 0.07% to 0.25% of bulk breast tumor cells, more in estrogen receptor-positive (ER+) compared with triple-negative (TN) subtype (0.1% to 0.75%, 0.18% to 0.33% of immune cells, respectively). CMP cells did not correlate with any of the myeloid lineages or stem cells in TME. CMP infiltration was higher in smaller tumors, with lower Nottingham grade, and in ER+/HER2- than in TNBC consistently in both SCAN-B and METABRIC cohorts. High CMP was significantly associated with a lower risk of brain metastasis and with better survival, particularly in ER+/HER2-. High CMP enriched epithelial-to-mesenchymal transition and angiogenesis pathways, and less cell proliferation and DNA repair gene sets. High CMP ER+/HER2- was associated with less immune cell infiltration and cytolytic activity ( P <0.001). CMP infiltration correlated with neoadjuvant chemoimmunotherapy response for both ER+/HER2- and TNBC in the ISPY-2 cohort (AUC=0.69 and 0.74, respectively)., Conclusions: CMP in BC is inversely associated with cell proliferation and brain metastasis, better response to immunotherapy, and survival. This is the first to report the clinical relevance of CMP infiltration in BC., Competing Interests: The authors declare no conflicts of interest., (Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
243. Validation Study of the Newly Proposed Refined Diagnostic Criteria for Malignant Phyllodes Tumor With 136 Borderline and Malignant Phyllodes Tumor Cases.
- Author
-
Li X, Nguyen TTA, Zhang J, Nayak A, Liu Y, Duckworth LA, Zhang G, Bakkar R, Agarwal I, Hou Y, Guo H, Huang X, Wei S, Yasmeen S, Khoury T, Huang H, Zhang H, Smith GH, Turashvili G, Peng L, Liu Y, Yang W, and Siziopikou KP
- Subjects
- Humans, Female, Adult, Middle Aged, Young Adult, Reproducibility of Results, Adolescent, Predictive Value of Tests, Aged, Stromal Cells pathology, Neoplasm Recurrence, Local, World Health Organization, Kaplan-Meier Estimate, Phyllodes Tumor pathology, Phyllodes Tumor diagnosis, Breast Neoplasms pathology, Breast Neoplasms diagnosis
- Abstract
The World Health Organization (WHO) diagnostic criteria for malignant phyllodes tumor (MPT) may miss a significant number of MPTs with metastatic potential. New refined diagnostic criteria (Refined Criteria) for MPT were recently proposed. The aim of this study is to validate the Refined Criteria. This validation study included 136 borderline (borderline phyllodes tumor [BoPT]) and MPT cases that were not included in the initial study. We evaluated tumor classifications based on both the Refined Criteria and the WHO criteria. The Refined Criteria defines MPT when these criteria are met (1) stromal overgrowth with ≥ 1 feature(s) of marked stromal cellularity, marked stromal cytologic atypia, or ≥10 mitoses per 10 high-power fields (10 mitoses/10 HPFs) or (2) marked stromal cellularity with ≥1 feature(s) of marked stromal cytologic atypia, ≥10 mitoses/10 HPFs or permeative border. The WHO criteria require all 5 morphologic features (stromal overgrowth, permeative border, marked stromal cellularity, marked stromal cytologic atypia, and ≥10 mitoses/10 HPFs) for an MPT diagnosis. Using the Refined Criteria, none of the 61 BoPTs developed metastasis and 40.0% of the 75 MPTs developed metastases; local recurrence was seen in 11.5% BoPTs and 25.3% MPTs. Using the WHO criteria, 9.6% of the 94 BoPTs developed metastases and 50.0% of the 42 MPTs developed metastases; 14.9% of the BoPTs had local recurrence and 28.6% of the MPTs had local recurrence. Nine (30.0%) of the 30 tumors that developed distant metastases were diagnosed as BoPTs by the WHO criteria. When we combined the 75 MPTs from this validation cohort with the 65 MPT cases from the published data using the Refined Criteria, 50 (35.7%) of the 140 MPTs developed metastases, whereas 8 cases with metastases were <5 cm. In the univariate analysis with log-rank test, stromal overgrowth, marked stromal cellularity, marked stromal cytologic atypia, ≥10 mitoses/10 HPFs, presence of heterologous components other than liposarcomatous component, and presence of stromal necrosis were significantly associated with the risk of metastasis (all with P < 0.05). In multivariate analysis with Cox proportional hazard regression, stromal overgrowth and marked stromal cellularity were significantly associated with metastasis (both with P < 0.001). The Refined Criteria are superior to the WHO criteria in predicting the clinical outcomes of BoPTs and MPTs. Using the Refined Criteria, 35.7% of 140 patients with MPT developed metastases, whereas none (0%) of the patients with BoPT developed metastases. Patients with MPT have a high metastatic rate; these patients may benefit from systemic chemotherapy or targeted therapies. In contrast, patients with BoPT may be managed with complete local excision alone without chemotherapy., Competing Interests: Conflicts of Interest and Source of Funding: X.L. has served as an advisor for Astra Zeneca, Roche, Eli Lilly, and Onviv, and Champions Oncology has funded research in Xiaoxian Li’ lab. S.W. has served as Breast Pathology Faculty Advisory Board for Daiichi Sankyo Inc. and AstraZeneca. For the remaining authors, none were declared., (Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
244. Detrimental Impact of Chemotherapy Dose Reduction or Discontinuation in Early Stage Triple-Negative Breast Cancer Treated With Pembrolizumab and Neoadjuvant Chemotherapy: A Multicenter Experience.
- Author
-
Krishnan J, Patel A, Roy AM, Alharbi M, Kapoor A, Yao S, Khoury T, Hong CC, Held N, Chakraborty A, Kaliniski P, Salman A, Catalfamo K, Attwood K, Kirtani V, Shaikh SS, Chaudhary LN, and Gandhi S
- Abstract
Background: Pembrolizumab combined with neoadjuvant chemotherapy (NAC) is the current standard of care in early stage triple-negative breast cancer (TNBC) based on higher event-free survival and pathological complete response (pCR) in Keynote-522 (KN-522) clinical trial. However, this aggressive five-drug regimen is associated with increased risks for immune-related adverse events (irAEs). We investigated real-world clinical outcomes and toxicity of this regimen as well as factors predictive of pCR and irAEs., Methods: We identified and abstracted data from 153 early-stage TNBC patients treated with the KN-522 regimen between July 1, 2021, and December 31, 2023, at 4 academic institutions in the U.S. Descriptive analysis was conducted, univariate and multivariate analyses were performed to identify factors associated with pCR and irAEs., Results: The median age was 52 years (interquartile range, 42-60years), with 66% White and 24% Black patients with stage I/II (67%), node-negative disease (58%), grade 3 (86%) tumors, and ≥1 comorbidities (68%). Approximately 21% discontinued pembrolizumab, because of toxicity; ∼50% received a lower relative dose intensity (RDI) of chemotherapy (dose reduction or discontinuation). Of the 153 patients, 99 (64.7%) achieved pCR and 83 (54%) experienced an irAE, with 18 (12%) having ≥ grade 3 irAE. The majority (90%) of the irAEs were observed during neoadjuvant phase. Stage I/II versus stage III disease (OR 1.55, CI 1.04-2.33, P = .03), age (OR 0.96, CI 0.93-0.99, P = .01) and full versus reduced RDI of NAC (OR 1.53, CI 1.04-2.26, P = .03) were associated with higher pCR rates on multivariate analyses. Fewer cycles of pembrolizumab were associated with a higher likelihood of irAEs (OR 1.52, CI 1.07-2.16, P = .02), likely explained by the early discontinuation and receipt of less than 8 cycles of pembrolizumab in patients who experienced irAEs., Conclusions: Our study validates the clinical efficacy of KN-522 regimen; however, we observed a higher incidence of irAEs (54%) in this real-world population. Lower stage and younger age were associated with higher likelihood of achieving pCR. Toxicity-related chemotherapy dose reduction or discontinuation was observed to adversely impact the likelihood of achieving pCR., Competing Interests: Disclosure All authors have declared no conflict of interest., (Copyright © 2024 The Author(s). Published by Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
245. Epidemiology of early vs. Late recurrence among women with Early-Stage estrogen Receptor-Positive breast cancer in the pathways study.
- Author
-
Chua AV Jr, Sheng H, Liang E, Gandhi S, Kwan ML, Ergas IJ, Roh JM, Laurent CA, Yan L, Khoury T, Ambrosone CB, Kushi LH, and Yao S
- Abstract
Background: Relatively little is known about the differences in prognostic factors for early vs late recurrence among women with early-stage estrogen receptor-positive (ER+) breast cancer., Methods: We analyzed factors related to early (<5 years) vs late (≥5 years) recurrence in 2,992 women with stage I-IIB ER+ breast cancer in the Pathways Study, a prospective cohort of women with breast cancer enrolled between 2006 and 2013, with ascertainment of recurrence and death through December 2021., Results: After a median follow-up of 13.3 years, 341 (13.8%) women had recurrences, including 181 (53.7%) with late recurrence. Higher stage and grade were associated with recurrence regardless of timing, whereas progesterone receptor (PR) negativity was associated with early but not late recurrence. Receipt of endocrine therapy was associated with reduced risk of overall recurrence, but the length of endocrine therapy was not significant in multivariable models. Minoritized racial and ethnic groups, including Asian, Black, and Hispanic women, had higher risk of early but not late recurrence, compared with non-Hispanic White women. The trend of higher risk of early recurrence among these groups remained after adjustment for clinical, demographic, and socioeconomic factors, but was statistically significant only in Asian women., Conclusions: Our study revealed potentially important distinctions for early vs late recurrence, including the associations with PR-negativity and self-identified race and ethnicity. Possible higher risk of early recurrence among Asian, Black, and Hispanic women provides novel evidence for the existence of disparities in cancer outcomes, even within the breast cancer subtype indicative of generally good prognosis., (© The Author(s) 2024. Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissions@oup.com.)
- Published
- 2024
- Full Text
- View/download PDF
246. Diagnosis and Management of Desmoid Fibromatosis of the Breast.
- Author
-
Kangas-Dick A, Ali M, Poss M, Khoury T, and Takabe K
- Abstract
Desmoid fibromatosis of the breast (also known as desmoid tumor of the breast) is a rare entity infrequently encountered by oncologists and surgeons caring for patients with breast disease. The current body of literature is highly reliant on case series and extrapolations from other sites of desmoid tumor-related disease. Much remains unclear regarding the pathological origins, natural history, and response to treatment of this condition. Traditional treatment strategies have centered on surgical resection, which may result in significantly disfiguring cosmetic and functional outcomes, frequent need for re-operation, and associated morbidity. There are limited data to support the superiority of upfront surgical resection when compared to medical therapy or watchful waiting strategies. Current treatment guidelines for desmoid tumors do not focus on the breast as a site of disease and are purposefully ambiguous due to the paucity of evidence available. We aim to review the literature concerning desmoid fibromatosis of the breast and propose an algorithm for current evidence-based management of this rare disease in the context of our experience with this pathology at a high-volume quaternary referral center., Competing Interests: The authors report no conflict of interest relevant to this article., (Copyright 2024, Kangas-Dick et al.)
- Published
- 2024
- Full Text
- View/download PDF
247. Emerging measurements for tumor-infiltrating lymphocytes in breast cancer.
- Author
-
Wu R, Horimoto Y, Oshi M, Benesch MGK, Khoury T, Takabe K, and Ishikawa T
- Subjects
- Humans, Female, Prognosis, Lymphocytes, Tumor-Infiltrating immunology, Tumor Microenvironment immunology, Breast Neoplasms immunology, Breast Neoplasms pathology
- Abstract
Tumor-infiltrating lymphocytes are a general term for lymphocytes or immune cells infiltrating the tumor microenvironment. Numerous studies have demonstrated tumor-infiltrating lymphocytes to be robust prognostic and predictive biomarkers in breast cancer. Recently, immune checkpoint inhibitors, which directly target tumor-infiltrating lymphocytes, have become part of standard of care treatment for triple-negative breast cancer. Surprisingly, tumor-infiltrating lymphocytes quantified by conventional methods do not predict response to immune checkpoint inhibitors, which highlights the heterogeneity of tumor-infiltrating lymphocytes and the complexity of the immune network in the tumor microenvironment. Tumor-infiltrating lymphocytes are composed of diverse immune cell populations, including cytotoxic CD8-positive T lymphocytes, B cells and myeloid cells. Traditionally, tumor-infiltrating lymphocytes in tumor stroma have been evaluated by histology. However, the standardization of this approach is limited, necessitating the use of various novel technologies to elucidate the heterogeneity in the tumor microenvironment. This review outlines the evaluation methods for tumor-infiltrating lymphocytes from conventional pathological approaches that evaluate intratumoral and stromal tumor-infiltrating lymphocytes such as immunohistochemistry, to the more recent advancements in computer tissue imaging using artificial intelligence, flow cytometry sorting and multi-omics analyses using high-throughput assays to estimate tumor-infiltrating lymphocytes from bulk tumor using immune signatures or deconvolution tools. We also discuss higher resolution technologies that enable the analysis of tumor-infiltrating lymphocytes heterogeneity such as single-cell analysis and spatial transcriptomics. As we approach the era of personalized medicine, it is important for clinicians to understand these technologies., (© The Author(s) 2024. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)
- Published
- 2024
- Full Text
- View/download PDF
248. Interpreting HER2-low at the lower end: Added challenge to the pathologists.
- Author
-
Khoury T
- Subjects
- Humans, Female, Biomarkers, Tumor metabolism, Receptor, ErbB-2 metabolism, Pathologists, Breast Neoplasms pathology
- Abstract
Competing Interests: Declaration of competing interest Thaer Khoury: Pathology faculty advisor for Daiichi Sankyo and AstraZeneca.
- Published
- 2024
- Full Text
- View/download PDF
249. CD163 + macrophages in the triple-negative breast tumor microenvironment are associated with improved survival in the Women's Circle of Health Study and the Women's Circle of Health Follow-Up Study.
- Author
-
Omilian AR, Cannioto R, Mendicino L, Stein L, Bshara W, Qin B, Bandera EV, Zeinomar N, Abrams SI, Hong CC, Yao S, Khoury T, and Ambrosone CB
- Subjects
- Humans, Female, Middle Aged, Follow-Up Studies, Prognosis, Adult, Tumor-Associated Macrophages metabolism, Tumor-Associated Macrophages immunology, Macrophages metabolism, Macrophages immunology, Macrophages pathology, Aged, Biomarkers, Tumor metabolism, Proportional Hazards Models, Tumor Microenvironment immunology, Antigens, Differentiation, Myelomonocytic metabolism, Antigens, CD metabolism, Receptors, Cell Surface metabolism, Triple Negative Breast Neoplasms mortality, Triple Negative Breast Neoplasms pathology, Triple Negative Breast Neoplasms immunology, Triple Negative Breast Neoplasms metabolism
- Abstract
Background: Tumor-associated macrophages (TAMs) are a prominent immune subpopulation in the tumor microenvironment that could potentially serve as therapeutic targets for breast cancer. Thus, it is important to characterize this cell population across different tumor subtypes including patterns of association with demographic and prognostic factors, and breast cancer outcomes., Methods: We investigated CD163
+ macrophages in relation to clinicopathologic variables and breast cancer outcomes in the Women's Circle of Health Study and Women's Circle of Health Follow-up Study populations of predominantly Black women with breast cancer. We evaluated 611 invasive breast tumor samples (507 from Black women, 104 from White women) with immunohistochemical staining of tissue microarray slides followed by digital image analysis. Multivariable Cox proportional hazards models were used to estimate hazard ratios for overall survival (OS) and breast cancer-specific survival (BCSS) for 546 cases with available survival data (median follow-up time 9.68 years (IQR: 7.43-12.33)., Results: Women with triple-negative breast cancer showed significantly improved OS in relation to increased levels of tumor-infiltrating CD163+ macrophages in age-adjusted (Q3 vs. Q1: HR = 0.36; 95% CI 0.16-0.83) and fully adjusted models (Q3 vs. Q1: HR = 0.30; 95% CI 0.12-0.73). A similar, but non-statistically significant, association was observed for BCSS. Macrophage infiltration in luminal and HER2+ tumors was not associated with OS or BCSS. In a multivariate regression model that adjusted for age, subtype, grade, and tumor size, there was no significant difference in CD163+ macrophage density between Black and White women (RR = 0.88; 95% CI 0.71-1.10)., Conclusions: In contrast to previous studies, we observed that higher densities of CD163+ macrophages are independently associated with improved OS and BCSS in women with invasive triple-negative breast cancer. Trial registration Not applicable., (© 2024. The Author(s).)- Published
- 2024
- Full Text
- View/download PDF
250. Selective breast/gynecologic pathology fellowship training in the United States: Experience of program directors.
- Author
-
Desouki MM, Hagemann IS, Khoury T, Fadare O, Bhargava R, Clark JL, Deavers MT, Jorns JM, Khan A, Cosar EF, Karabakhtsian RG, Klein ME, Pinto A, and Ali M
- Abstract
Published data on combined breast and gynecologic [breast/gyn] surgical pathology fellowship training programs are limited. Our study aimed to survey the landscape of such fellowships in the United States (US), including specific information about their characteristics and the educational activities therein. Using web searches, we identified programs offering combined breast/gyn surgical pathology fellowship training. We developed a 26-item questionnaire asking program directors to report on the characteristics of their fellowship training structure. The search revealed 25 academic based programs offering one-year combined breast/gyn fellowship training, predominantly located (40 %) in the Northeast area. The following data was obtained: 44 % of the programs were accredited by the ACGME, 82 % required >19 weeks of breast and gyn service, and 69.6 % accepted the common application, 54.5 % of programs require completion of a research project for graduation. An annual average of 3000 breast and 3000 gyn cases appears to be the usual volume of cases. Interestingly, only 36 % of the program directors are graduates of a combined breast/gyn fellowship program. In conclusion, we present the most comprehensive and up-to-date census of combined breast/gyn pathology fellowships in the US. Our study provides valuable information on the current state of combined breast/gyn pathology fellowship training. The information will be helpful to current and prospective trainees, as well as program leaders., Competing Interests: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (© 2023 The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.